Patents Assigned to Betagene, Inc
-
Patent number: 6194176Abstract: The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.Type: GrantFiled: January 17, 1997Date of Patent: February 27, 2001Assignees: Board of Regents, The University of Texas System, Betagene, Inc.Inventors: Christopher B. Newgard, Philippe Halban, Karl D. Normington, Samuel A. Clark, Anice E. Thigpen, Christian Quaade, Fred Kruse
-
Patent number: 6171856Abstract: The present invention relates to methods and compositions for the treatment of diabetes involving free radicals. In particular, the present invention is directed to the treatment or prophylactic intervention of diabetes. The present invention demonstrates that MnSOD can play a protective role against cytokine killing, and provides strategies for engineering cell lines as islet surrogates for transplantation therapy of diabetes mellitus. Further, the present invention shows that &bgr;-cell destruction and dysfunction in adipogenic diabetes is mediated via fatty acids. Methods and compositions for ameliorating this disorder are provided herein.Type: GrantFiled: July 30, 1998Date of Patent: January 9, 2001Assignees: Board of Regents, The University of Texas System, Betagene, IncInventors: Anice Thigpen, Hans-Ewald Hohmeier, Christopher B. Newgard, Roger H. Unger, Michio Shimabukuro, Guoxun Chen, Christopher J. Rhodes, Sigrun R. H{umlaut over (u)}gl, Sharon Cousin
-
Patent number: 6110707Abstract: The present invention a provides methods for production of heterologous polypeptides, for example amylin, using recombinantly engineered cell lines. Also described are methods engineering cells for high level expression, methods of large scale heterologous protein production, methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines, and methods for isolating novel amylin receptors.Type: GrantFiled: January 17, 1997Date of Patent: August 29, 2000Assignees: Board of Regents, The University of Texas System, Betagene, Inc.Inventors: Christopher B. Newgard, Philippe Halban, Karl D. Normington, Samuel A. Clark, Anice E. Thigpen, Christian Quaade, Fred Kruse, Dennis McGarry
-
Patent number: 6087129Abstract: The present invention a provides methods for production of heterologous polypeptides using a variety recombinantly engineered secretory cell lines. The common feature of these cell lines is the absence of expression of at least one endogenous polypeptide. The host cell machinery normally used to produce the endogenous polypeptide is then usurped for the purpose of making the heterologous polypeptide. Also described are methods engineering cells for high level expression, methods of large scale protein production, and methods for treatment of disease in vivo using viral delivery systems and recombinant cell lines.Type: GrantFiled: January 19, 1996Date of Patent: July 11, 2000Assignees: Betagene, Inc., Board of Regents, The University of Texas SystemInventors: Christopher B. Newgard, Karl D. Normington, Samuel A. Clark, Anice E. Thigpen, Christian Quaade, Fred Kruse
-
Patent number: 5891717Abstract: Disclosed are compositions and methods for inhibiting hexokinase enzymes in mammalian cells. Specifically provided are proteins that stimulate the production of trehalose-6-phosphate and their respective genes; hexokinase-specific ribozymes and genes encoding such constructs; and agents that competitively reduce hexokinase activity, e.g., by displacing hexokinase from mitochondria, and their respective genes. The latter group of agents includes inactive hexokinases and fragments thereof that retain mitochondrial binding functions and hexokinase-glucokinase chimeras that further substitute glucokinase activity for hexokinase activity. Mammalian cells including such hexokinase inhibitors, methods of making such cells and various in vitro and in vivo methods of using cells with reduced hexokinase activity are also described herein.Type: GrantFiled: January 19, 1996Date of Patent: April 6, 1999Assignees: Betagene, Inc., Board of Regents, The University of Texas SystemInventors: Christopher B. Newgard, He-Ping Han, Thomas C. Becker, John E. Wilson
-
Patent number: 5854067Abstract: Disclosed are compositions and methods for inhibiting hexokinase enzymes in mammalian cells. Specifically provided are proteins that stimulate the production of trehalose-6-phosphate and their respective genes; hexokinase-specific ribozymes and genes encoding such constructs; and agents that competitively reduce hexokinase activity, e.g., by displacing hexokinase from mitochondria, and their respective genes. The latter group of agents includes inactive hexokinases and fragments thereof that retain mitochondrial binding functions and hexokinase-glucokinase chimeras that further substitute glucokinase activity for hexokinase activity. Mammalian cells including such hexokinase inhibitors, methods of making such cells and various in vitro and in vivo methods of using cells with reduced hexokinase activity are also described herein.Type: GrantFiled: January 19, 1996Date of Patent: December 29, 1998Assignees: Board of Regents, The University of texas System, Betagene, Inc.Inventors: Christopher B. Newgard, He-Ping Han, Karl D. Normington